Archived explainer. For the current picture see today's LLY page.
Why Is ELI LILLY AND CO (LLY) Stock Moving Today?
By the Top Tier Newswire AI Desk · September 2, 2026 at 1:28 AM ET · reviewed against 14 wire stories
ELI LILLY AND CO (LLY) is drawing unusual attention today. Our newswire has captured 14 stories on LLY across 9 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Eli Lilly and Company stock is moving lower today after falling 7.9% over the past eight sessions. The decline follows the announcement of a $2.875 billion cash acquisition of Merida Biosciences, which is expected to close in Q4 2026. The deal has drawn attention from analysts and investors, with BMO reiterating an Outperform rating on the stock based on the acquisition. Meanwhile, the FDA has taken steps to address safety concerns around compounded GLP-1 drugs, and Eli Lilly faces broader industry headwinds as insurers reduce coverage of GLP-1 therapies. Recent insider transactions also show executives selling shares, adding to investor caution.
What Happened
Eli Lilly announced its agreement to acquire Merida Biosciences for up to $2.875 billion in cash, a move expected to strengthen its immune-focused drug development pipeline. The acquisition is part of a broader trend of Big Pharma paying high premiums for specialized biotech platforms. BMO reiterated its Outperform rating on the stock, citing the strategic value of the deal. The Motley Fool highlighted the potential for new Zepbound studies to benefit investors, while Yahoo Finance noted the FDA’s recent approval of a specific tool to defend against payer resistance in the GLP-1 market. Meanwhile, Eli Lilly’s recent 52-week trial data showed improved efficacy for Taltz and Zepbound in treating psoriatic disease and obesity.
What The Data Shows
Eli Lilly’s stock has moved from a 52-week high of $1,292.65 to $1,166.96 as of the most recent close. The company has a market cap of $1.05 trillion and a P/E ratio of 38.8. Revenue has grown by 49.6% in the trailing twelve months, with a net margin of 33.5%. Over the past 36 hours, unusual options activity included a notable $43,000 call premium. Insider transactions in the last 90 days totaled four sales, with no buys reported. Congressional trades show six sales and fifteen buys in the same period. The stock has printed 36 fresh 52-week lows on September 1, 2026.
What To Watch
Eli Lilly is scheduled to participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026. Investors should monitor the company’s progress in closing the Merida acquisition and the impact of its GLP-1 drug coverage challenges.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
LLY · Sep 2 session (5-min) · +0.12% vs prior close · updated 8:45 PM ETAI sentiment, last 36h · averaged over 14 stories · 63/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
11d agoMorningstarBULLISH 63M&A
Roche, Simcere Pharma Strike Drug Licensing Deal
The agreement is the latest tie-up between Western pharmaceutical majors and Chinese drugmakers. U.S.-based Bristol-Myers Squibb in May struck a strategic partnership and licensing deal with Hengrui Pharmaceuticals that could be worth more than $15 billion. Earlier this year, Eli Lilly entered into a partnership with Innovent Biologics potentially valued at up to $8.5 billion.
11d agoThe Motley FoolBULLISH 73Product/PR
This New Zepbound Study Could Be Great News for Eli Lilly Investors
The high-flying healthcare leader looks unstoppable right now.
11d agoYahoo TopBULLISH 68Product/PR
Insurers Are Pulling Back From GLP-1 Drugs. The FDA Just Handed Eli Lilly Its Best Weapon Yet
Employer coverage of GLP-1 drugs is collapsing heading into 2027, but the FDA just gave Eli Lilly a specific piece of ammunition that could change the conversation in payer meetings for at least one slice of that market.
BMO reiterates Eli Lilly stock Outperform on Merida acquisition
BMO reiterates Eli Lilly stock Outperform on Merida acquisition
11d agoPR NewswireBULLISH 55General
Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference
INDIANAPOLIS, Sept. 1, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026. Ilya Yuffa, executive vice president and president, Lilly USA and Global Customer Capabilities, will take...
11d agoYahoo TopBULLISH 67Analyst
Jim Cramer: This Little-Talked-About Drug Could Target the “Biggest Market of All Time” Aside From Eli Lilly’s GLP-1 Drugs
Jim Cramer is flagging an Amgen drug that Wall Street has largely ignored, and he thinks the cardiovascular opportunity behind it could rival the most valuable pharmaceutical market ever created.
12d agoStocktwits NewsBULLISH 67M&A
SLS, IBRX Stocks Post August Gains: Eli Lilly’s Latest $2.9B Deal Has Retail Traders Bracing For An ‘M&A Rampage’
Retail traders viewed the Merida acquisition as evidence that Big Pharma will pay rich premiums for immune-focused platforms.
12d agoThe Motley FoolBULLISH 63M&A
Eli Lilly Is Acquiring Merdia Biosciences for Up to $2.88 Billion. Here's What That Means for Investors.
Hardly for the first time recently, the company is making a pricey acquisition.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →